45,000 Shares in Celldex Therapeutics, Inc. (NASDAQ:CLDX) Purchased by Healthcare of Ontario Pension Plan Trust Fund

Posted by Defense World Staff on Feb 27th, 2023

Healthcare of Ontario Pension Plan Trust Fund acquired a new position in Celldex Therapeutics, Inc. (NASDAQ:CLDX – Get Rating) in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 45,000 shares of the biopharmaceutical company’s stock, valued at approximately $1,265,000. Healthcare of Ontario Pension Plan Trust Fund owned 0.10% of Celldex Therapeutics as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Silverarc Capital Management LLC increased its position in Celldex Therapeutics by 0.9% in the first quarter. Silverarc Capital Management LLC now owns 45,538 shares of the biopharmaceutical company’s stock worth $256,000 after purchasing an additional 406 shares during the period. Point72 Hong Kong Ltd grew its position in shares of Celldex Therapeutics by 57.9% during the 1st quarter. Point72 Hong Kong Ltd now owns 1,394 shares of the biopharmaceutical company’s stock worth $47,000 after buying an additional 511 shares during the period. Nisa Investment Advisors LLC grew its position in shares of Celldex Therapeutics by 109.0% during the 3rd quarter. Nisa Investment Advisors LLC now owns 1,024 shares of the biopharmaceutical company’s stock worth $36,000 after buying an additional 534 shares during the period. Virtus ETF Advisers LLC grew its position in shares of Celldex Therapeutics by 16.6% during the 2nd quarter. Virtus ETF Advisers LLC now owns 4,816 shares of the biopharmaceutical company’s stock worth $130,000 after buying an additional 685 shares during the period. Finally, TSP Capital Management Group LLC grew its position in shares of Celldex Therapeutics by 0.3% during the 3rd quarter. TSP Capital Management Group LLC now owns 267,295 shares of the biopharmaceutical company’s stock worth $7,514,000 after buying an additional 750 shares during the period.

Celldex Therapeutics Trading Down 3.3 %

Shares of CLDX opened at $40.12 on Monday. The stock has a 50 day simple moving average of $44.36 and a 200 day simple moving average of $37.08. Celldex Therapeutics, Inc. has a 52-week low of $19.85 and a 52-week high of $48.40.

Analyst Ratings Changes

Several research firms have recently issued reports on CLDX. Guggenheim decreased their target price on Celldex Therapeutics from $68.00 to $63.00 and set a “buy” rating for the company in a research report on Friday, November 11th. StockNews.com upgraded Celldex Therapeutics to a “sell” rating in a research report on Tuesday, December 27th. One research analyst has rated the stock with a sell rating and four have assigned a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $66.67.

Celldex Therapeutics Company Profile

(Get Rating)

Celldex Therapeutics, Inc engages in the business of development, manufacturing and commercialization of novel therapeutics for human health care. Its drug candidates have the ability to engage the human immune system and directly inhibit tumors to treat specific types of cancer and other diseases. Its pipeline includes Varlilumab, CDX-1140, and CDX-301, and CDX-3379.